Liquidia Settles All Litigation with United Therapeutics, Keeps YUTREPIA on Market for PAH

Liquidia reached a global settlement with United Therapeutics resolving all six pending lawsuits, including patent infringement, trade secret, breach of contract, and antitrust claims. As part of the deal, Liquidia will pay a net $380.7 million in installments during 2026-2027, will not appeal the recent court ruling on the '327 patent, has submitted a label supplement to remove the PH-ILD indication from YUTREPIA, and will cease promotion for PH-ILD while maintaining uninterrupted commercialization for PAH. The settlement provides regulatory and commercial certainty for YUTREPIA in PAH without altering its approved status or ongoing development programs for other indications.

Key facts

Filed: Oct 14, 2026, 05:44 AM
Event: Partnership / licensing deal
Direction: Neutral
Company: LQDALiquidia
Asset: treprostinil
Source: Company press release
Confidence: Sourced
Q3 2026 sales: $222.7 million
cash position: $396.1 million
settlement payment: $380.7 million

Source excerpt

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Fully resolves all six ongoing lawsuits between the companies Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH) Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics Strong financial position with $222.7 million in Q3’26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026 Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption. Liquidia CEO Dr. Roger Jeffs said: “We are always guided by our commitment to act in the best interests of patients in everything we do. Today’s agreement fully resolves years of litigation and prov

Company press release